Compare Novo Nordisk A/S (NVO) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Weibo Corp — how do they compare? Novo Nordisk A/S trades at $38.4 (market cap $165.31B), while Weibo Corp trades at $6.53 (market cap $1.56B). The key difference: Novo Nordisk A/S is far larger — about 106× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Weibo Corp for 102 Days on average.
| NVO | WB | |
|---|---|---|
Market Cap | $165.31B | $1.56B |
Volume | 11,432,838 | 812,503 |
Sector | Health | Media |
52-Week High | $63.98 | $12.37 |
52-Week Low | $35.29 | $6.33 |
Typical Hold Time | 116 Days | 102 Days |
Enterprise Value | $179.56B | $786.69M |
Dividend Yield | 4.71% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Weibo (WB) trades at $6.55, up 1.08% on the day, with a bearish technical signal. The stock is fundamentally attractive with a low P/E of 5.32 and P/B of 0.4, while profitability remains solid with a net income margin of 17.78%. Recent Q2 2026 earnings beat expectations, though revenue growth is modest. Cash flow trends show volatility, with a significant net outflow in 2024.
The outlook is mixed; deep-value metrics and strong cash generation offer upside, but declining user metrics and advertising headwinds pose risks. Analyst consensus is divided, leaning slightly toward Hold. The stock presents a value opportunity for patient investors, contingent on stabilizing user engagement and advertising demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
